RecruitingNot ApplicableNCT05517928

A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

Exploratory Study of the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis


Sponsor

Mayo Clinic

Enrollment

30 participants

Start Date

Mar 3, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Lactobacillus rhamnosus GG, a drug called Omeprazole, and others for people with healthy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOmeprazole

40 MG oral capsules daily

DIETARY_SUPPLEMENTLactobacillus rhamnosus GG

Given as Culturelle Digestive Probiotic in the form of oral capsules daily

DRUGPlacebo

Oral capsules daily that look exactly like the study drug, but contains to active ingredient


Locations(1)

Mayo Clinic Arizona

Scottsdale, Arizona, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05517928


Related Trials